ZNTL
Zentalis Pharmaceuticals, Inc. · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website zentalis.com
- Employees(FY) 156
- ISIN US98943L1070
Performance
-3.59%
1W
-6.29%
1M
-6.94%
3M
+7.58%
6M
-20.33%
YTD
-54.64%
1Y
Profile
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics: and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
Investment Analysis Report: ZNTL
Overview
ZNTL is a company operating in the Health Technology sector, specifically in the Biotechnology industry. The company has a market capitalization of $917,832,036. In this report, we will conduct a comprehensive analysis of ZNTL's financial statements over the past three years, focusing on the Balance Shee...
Technical Analysis of ZNTL 2024-05-10
Overview:
In analyzing the technical indicators for ZNTL over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days.
Trend Analysis:
- Moving Averages (MA): The 5-day Moving Average (MA) has been consistently rising, ind...
Recent News & Updates
- 2024-05-14 07:00
- 2024-05-13 19:00
- 2024-05-08 10:27
- 2024-05-08 07:31
- 2024-05-07 21:04
- 2024-05-07 07:00
- 2024-05-07 01:54
- 2024-05-06 19:00
- 2024-05-01 17:30
- 2024-05-01 05:30
- 2024-04-02 16:05
- 2024-04-02 04:05
- 2024-04-01 17:30
- 2024-04-01 05:30
- 2024-03-01 18:00
- 2024-03-01 05:00
- 2024-02-29 05:50
- 2024-02-28 09:55
- 2024-02-28 07:00
- 2024-02-27 20:55
- 2024-02-27 19:01
- 2024-02-27 18:00
- 2024-02-27 07:00
- 2024-02-26 18:00
- 2024-02-14 09:35
- 2024-02-13 20:35
- 2024-02-13 07:00
- 2024-02-12 18:00
- 2024-02-08 12:00
- 2024-02-07 23:00
Page 1 of 5
previousnext